Allopurinol 300mg: A Comprehensive Guide to Gout Treatment, Dosage, Side Effects and Affordable Generic Options

Allopurinol is the most widely prescribed xanthine oxidase inhibitor worldwide and the cornerstone of long-term gout management. First approved in the 1960s, it remains the first-line urate-lowering therapy recommended by major rheumatology guidelines including the American College of Rheumatology and the European League Against Rheumatism. Available as an inexpensive generic from numerous manufacturers, allopurinol offers effective, long-term control of serum uric acid levels for millions of gout patients. This guide covers how allopurinol works, appropriate dosing, safety considerations, and realistic pricing for generic versions.

What Is Gout?

Gout is the most common form of inflammatory arthritis in adults, affecting an estimated 8.3 million people in the United States and approximately 1 to 2 percent of the adult population in many developed countries. It is caused by the deposition of monosodium urate crystals in joints and surrounding tissues, triggering intense inflammatory responses. Gout typically presents as sudden, severe attacks of pain, swelling, redness, and tenderness in one or more joints — most commonly the first metatarsophalangeal joint at the base of the big toe, known as podagra, but also affecting ankles, knees, wrists, and elbows.

The underlying driver of gout is hyperuricemia — elevated serum uric acid levels above the saturation point for urate crystal formation, approximately 6.8 mg/dL. Uric acid is the end product of purine metabolism in humans, and unlike most mammals, humans lack the enzyme uricase that breaks uric acid down further. When uric acid levels remain elevated over time, crystals accumulate in joints, cartilage, and soft tissues, leading to recurrent acute attacks, chronic joint damage, and tophus formation — visible urate crystal deposits under the skin.

What Is Allopurinol?

Allopurinol is a structural analog of hypoxanthine, a naturally occurring purine. It works by inhibiting xanthine oxidase, the enzyme responsible for converting hypoxanthine to xanthine and xanthine to uric acid — the final two steps in uric acid production. By blocking this enzyme, allopurinol reduces the body’s production of uric acid, lowering serum urate levels and allowing existing urate crystal deposits to gradually dissolve over time.

Allopurinol is available in tablet form in strengths of 100 mg and 300 mg. The 300 mg tablet is the most commonly prescribed strength for maintenance therapy. Generic allopurinol is manufactured by numerous pharmaceutical companies worldwide and is widely available at low cost. It is important to understand that allopurinol is not a pain reliever or anti-inflammatory agent — it does not treat acute gout flares directly. Its role is long-term urate reduction to prevent future flares, dissolve existing crystal deposits, and prevent joint damage and tophus formation.

Mechanism of Action

Allopurinol itself is a prodrug — it is rapidly metabolized by xanthine oxidase into its active metabolite, oxypurinol, also called alloxanthine, which is the primary inhibitor of the enzyme. Oxypurinol binds to the molybdenum-pterin center of xanthine oxidase, forming a stable complex that prevents the enzyme from converting its substrates. Unlike some other inhibitors, oxypurinol’s binding is relatively long-lasting, providing sustained enzyme inhibition even after the parent drug has been cleared from the circulation.

The key pharmacologic effects are reduced uric acid production — by inhibiting xanthine oxidase, allopurinol shifts purine metabolism toward the formation of oxypurinol and xanthine, which are more soluble and readily excreted, rather than uric acid. Steady-state serum uric acid reductions of 20 to 50 percent are typical, depending on baseline levels and dosage. Enhanced uric acid excretion occurs because xanthine and hypoxanthine are more water-soluble than uric acid and are more easily excreted in urine, reducing the urate burden.

Uses and Indications

Allopurinol is primarily indicated for chronic gout management — long-term control to lower serum urate levels and prevent recurrent acute flares, tophus formation, and joint damage. It is recommended for patients with frequent flares, two or more per year, tophi, or radiographic evidence of joint damage, as recommended by the 2020 ACR guideline.

Additional indications include tumor lysis syndrome prophylaxis in patients receiving chemotherapy for hematologic malignancies such as leukemia and lymphoma who are at high risk for rapid cell lysis releasing large amounts of purines and causing dangerous hyperuricemia and kidney injury. Allopurinol is also used for recurrent uric acid kidney stones — it can reduce urinary uric acid excretion and help prevent recurrent calcium oxalate and uric acid stones in hyperuricemic patients. For Lesch-Nyhan syndrome, a rare genetic disorder causing severe hyperuricemia, allopurinol is used to manage uric acid levels, though it does not address the neurological aspects of the condition.

Dosage and Administration

Appropriate allopurinol dosing is critical for effectiveness and safety. The traditional approach of starting at a low dose and slowly titrating upward has been reinforced by modern guidelines to minimize the risk of acute flares when starting treatment and to reduce the risk of severe hypersensitivity reactions.

For standard gout management with normal renal function, the starting dose is 100 mg once daily, increased by 100 mg every 2 to 5 weeks based on serum urate levels. The typical target dose is 300 to 600 mg per day, though some patients need up to 800 to 900 mg per day. For moderate renal impairment with creatinine clearance of 30 to 59 mL per minute, the starting dose remains 100 mg once daily but titration is slower, with a maximum of 300 to 400 mg per day in divided doses. For severe renal impairment with creatinine clearance of 10 to 29 mL per minute, the starting dose is 100 mg every other day or 50 mg per day, with very gradual titration — limited by renal clearance, as oxypurinol accumulates. Patients on hemodialysis typically take 100 mg after each dialysis session or 100 mg every 48 hours.

The treatment goal is to maintain serum urate below 6.0 mg/dL, or below 5.0 mg/dL in patients with tophi. This target should be confirmed with regular blood testing — typically every 2 to 5 weeks during dose titration and every 6 to 12 months once stable. Important administration notes include taking the medication once daily, preferably after a meal to reduce gastrointestinal upset, maintaining adequate hydration with at least 2 liters of fluid daily to promote uric acid excretion and reduce the risk of kidney stone formation, and not stopping allopurinol during an acute gout flare — continuing urate-lowering therapy during a flare is now recommended by ACR guidelines. Concomitant anti-inflammatory prophylaxis with colchicine, NSAIDs, or low-dose corticosteroids is recommended for the first 3 to 6 months after starting allopurinol to prevent flares triggered by rapid changes in urate levels.

Side Effects and Safety Considerations

Common side effects of allopurinol include skin rash affecting 2 to 5 percent of patients — the most common adverse effect, ranging from mild to severe — gastrointestinal upset including nausea, diarrhea, and vomiting in 1 to 3 percent, headache in 1 to 2 percent, elevated liver enzymes that are usually mild and transient, and drowsiness or fatigue in approximately 1 percent of patients.

Serious safety warnings include allopurinol hypersensitivity syndrome, also known as AHS, which can progress to Stevens-Johnson syndrome and toxic epidermal necrolysis — rare but potentially life-threatening hypersensitivity reactions. Risk factors include renal impairment, especially if the starting dose is not adjusted, HLA-B*5801 allele carriage which is more common in certain Asian and African populations, and high starting doses. Patients should stop allopurinol and seek immediate medical attention if they develop a rash, especially if accompanied by fever, mucosal involvement, or blistering. Acute gout flare upon initiation is a well-recognized phenomenon — rapid reduction in serum urate can precipitate acute flares in the first months of treatment, which is why anti-inflammatory prophylaxis is recommended for the first 3 to 6 months.

Rare but reported hepatotoxicity requires liver function monitoring if symptoms suggestive of liver injury develop, including jaundice, dark urine, severe fatigue, or right upper quadrant pain. Renal impairment considerations are critical — allopurinol and its metabolite oxypurinol are primarily renally excreted, and in renal impairment, oxypurinol can accumulate, increasing the risk of both hypersensitivity reactions and toxicity. Dose adjustment is essential. HLA-B*5801 testing may be considered in populations with high prevalence of this allele, including Han Chinese, Thai, and some African American populations, as carriage significantly increases the risk of severe hypersensitivity reactions.

Allopurinol vs. Febuxostat

Allopurinol is a purine analog xanthine oxidase inhibitor dosed once daily with a typical starting dose of 100 mg per day and a typical target dose of 300 to 600 mg per day. Renal adjustment is required, with dose reduction needed in renal impairment. It is the preferred first-line agent according to the 2020 ACR guideline and has no cardiovascular safety signal. Its generic cost is very low, among the cheapest gout medications available. It is effective in most patients at appropriate doses.

Febuxostat is a non-purine, selective xanthine oxidase inhibitor also dosed once daily, with a typical starting dose of 40 mg per day and a typical target dose of 40 to 80 mg per day. Unlike allopurinol, no dose adjustment is required for mild or moderate renal impairment. It is an alternative if allopurinol is not tolerated or contraindicated. The FDA has issued a boxed warning for cardiovascular death risk based on the CARES trial, though the Feburic trial showed no excess — it should be used with caution in patients with established cardiovascular disease. Generic febuxostat is available but generally more expensive than allopurinol. Its urate-lowering effectiveness at approved doses is similar to or slightly superior to allopurinol.

The 2020 ACR guideline conditionally recommends allopurinol over febuxostat as first-line urate-lowering therapy, primarily due to allopurinol’s longer track record, lower cost, and absence of the cardiovascular safety concerns raised by the CARES trial. However, febuxostat remains an important alternative for patients who cannot tolerate allopurinol or have significant renal impairment.

Generic Allopurinol Pricing and Cost Comparison

Allopurinol is one of the most affordable long-term medications available, which is a significant advantage for the millions of gout patients who require lifelong urate-lowering therapy.

In India, generic allopurinol 300 mg tablets are produced by numerous manufacturers at very competitive prices. A pack of 10 tablets of generic allopurinol 300 mg typically ranges from 1 to 2.50 USD, approximately 80 to 200 Indian rupees, depending on the manufacturer and pharmacy. A 30-tablet supply, providing one month of treatment at one tablet daily, generally ranges from 3 to 7.50 USD. These are estimate ranges and can vary based on the specific manufacturer, formulation, and retailer.

In the United States, generic allopurinol has historically been very inexpensive. A 30-day supply of generic allopurinol 300 mg at major US retail pharmacies typically ranges from 10 to 35 USD without insurance, depending on the pharmacy, location, and discount program. Some discount coupons can bring this as low as approximately 4 to 8 USD for a 30-day supply. Brand-name Zyloprim, if still available, would cost substantially more — typically 150 to 300 USD or more per month.

For patients requiring higher doses of 400 to 600 mg per day or more, the monthly cost naturally increases proportionally — a 60-tablet supply of generic allopurinol 300 mg in India might range from 6 to 15 USD, and in the US from 15 to 50 USD without insurance.

To explore available generic allopurinol formulations and strengths, visit our arthritis product category for an overview of options.

For a patient taking 300 mg daily for a year, generic allopurinol in India costs approximately 36 to 90 USD annually, compared to approximately 120 to 420 USD annually for US generic allopurinol at retail prices. For lifelong therapy spanning decades, these cost differences are substantial, particularly for patients in lower-income settings or those without comprehensive insurance coverage.

Clinical Evidence and Effectiveness

Multiple studies have demonstrated that allopurinol 300 mg per day reduces serum urate by an average of 30 to 50 percent from baseline, with most patients achieving target urate levels below 6.0 mg/dL at doses of 300 to 600 mg per day. A 2015 meta-analysis found that allopurinol 300 mg per day achieves target urate in approximately 30 to 40 percent of patients, with higher doses needed for the remainder.

The landmark study by the British Society for Rheumatology demonstrated that sustained urate-lowering therapy with allopurinol significantly reduces the frequency of acute gout flares over time — from an average of 2 to 3 flares per year before treatment to fewer than 1 per year in well-controlled patients. Long-term allopurinol therapy at doses sufficient to maintain serum urate below 6.0 mg/dL leads to gradual dissolution of tophi — complete resolution typically requires years of sustained urate control, but measurable reduction is often seen within 6 to 12 months.

By reducing uric acid crystal deposition in renal tissue and reducing the risk of uric acid stones, allopurinol may offer renal protective benefits in hyperuricemic patients, though dedicated outcome trials are limited. The 2018 FAST trial, a large pragmatic randomized trial involving over 6,000 patients in the UK, found no significant difference in cardiovascular outcomes or gout-related events between allopurinol and febuxostat over a median follow-up of approximately 3 years, providing reassurance about allopurinol’s long-term safety profile. The ACR 2020 guideline strongly recommends starting allopurinol at no more than 100 mg per day and titrating upward — this approach has been shown to reduce the risk of AHS and improve tolerability compared to higher starting doses.

Drug Interactions

Allopurinol can potentiate warfarin’s effect, increasing the risk of bleeding — INR monitoring is recommended when starting or stopping allopurinol in patients on warfarin. Allopurinol inhibits xanthine oxidase, which is involved in the metabolism of azathioprine and 6-mercaptopurine — concurrent use can lead to toxic accumulation, so doses of these immunosuppressants typically need to be reduced by 50 to 75 percent when allopurinol is added, with close monitoring under specialist supervision.

Allopurinol can increase cyclosporine levels, so monitoring of cyclosporine concentrations is recommended. Allopurinol may slightly increase theophylline levels, though monitoring is generally not required at standard allopurinol doses. Enzyme inducers such as phenobarbital, phenytoin, and other similar drugs can accelerate allopurinol metabolism, potentially reducing its effectiveness — higher doses may be needed. Diuretics, both thiazide and loop, can increase serum urate levels, potentially counteracting allopurinol’s effect — patients on diuretics may require higher allopurinol doses to achieve target urate.

Practical Tips for Gout Patients

Start low and go slow — the 100 mg starting dose is intentional and protective. Take your daily allopurinol at the same time each day, ideally after a meal. Stay well hydrated — aim for at least 2 liters of fluid daily to help kidneys excrete uric acid and reduce stone risk. Do not stop allopurinol during a gout flare — continuing therapy prevents rebound hyperuricemia; use your prescribed flare treatment such as NSAID, colchicine, or steroid for the acute episode. Get your serum uric acid checked regularly — every 2 to 5 weeks during dose adjustment and every 6 to 12 months once stable. The target is below 6.0 mg/dL, or below 5.0 mg/dL if you have tophi. Limit alcohol, especially beer and spirits, which raise uric acid levels, and limit high-purine foods including red meat, organ meats, certain seafood such as anchovies, sardines, and mussels, and sugary drinks containing high-fructose corn syrup.

FAQ

How long does it take for allopurinol to work?

Allopurinol begins reducing uric acid production within hours of the first dose, but it takes weeks to months to reach steady-state serum urate levels and for existing crystal deposits to begin dissolving. Most patients see a meaningful reduction in serum uric acid within 2 to 4 weeks of starting an appropriate dose, and the frequency of acute gout flares typically begins to decrease within 3 to 6 months of sustained urate control. Full tophus resolution, when present, may take years.

Do I need to take allopurinol for life?

For most gout patients, yes — gout is a chronic metabolic condition, and urate-lowering therapy is typically lifelong. If allopurinol is stopped, serum urate levels will return to pre-treatment levels within days to weeks, and crystal deposition, flares, and joint damage will resume their natural progression. Some patients with very mild, infrequent gout triggered by a reversible cause may be able to discontinue therapy under medical supervision, but this is uncommon.

Will allopurinol cure my gout?

Allopurinol does not cure gout in the sense of eliminating the underlying metabolic tendency toward hyperuricemia. However, it effectively controls the condition when taken consistently — maintaining serum urate below the saturation point prevents new crystal formation and allows existing deposits to dissolve. Many patients on long-term allopurinol at appropriate doses experience zero or very few flares and avoid the joint damage and tophi that can occur without treatment. In this sense, allopurinol can effectively put gout into remission for most patients.

What is the difference between allopurinol 100 mg and 300 mg?

The 100 mg tablet is typically used as a starting dose and for patients with renal impairment who require lower doses. The 300 mg tablet is the standard maintenance strength — most patients with normal renal function will eventually be titrated to 300 mg per day or higher, often 300 to 600 mg per day. The 300 mg strength is more convenient for patients who have reached their maintenance dose, as it avoids the need to split or take multiple 100 mg tablets.

Can allopurinol cause more gout attacks when I first start it?

Yes, this is a well-recognized phenomenon. Rapidly lowering serum uric acid can destabilize existing urate crystal deposits in joints, triggering acute flares. This is why anti-inflammatory prophylaxis with colchicine, NSAIDs, or low-dose corticosteroids is recommended for the first 3 to 6 months after starting allopurinol. The prophylaxis does not treat the underlying uric acid problem but prevents the inflammatory response to crystal mobilization. Importantly, this temporary increase in flare risk does not mean allopurinol is not working — it is a transitional phenomenon that resolves as urate levels stabilize.

Medical Disclaimer

This article is for informational purposes only and does not constitute medical advice. Gout management requires individualized diagnosis and treatment by a qualified healthcare professional. Allopurinol dosing, titration, and monitoring should be guided by your treating physician, with regular blood tests to assess serum urate levels, kidney function, and liver function as appropriate. Prices provided are estimates only and vary by manufacturer, pharmacy, location, and time — always confirm current pricing with your pharmacist or healthcare provider. Do not start, stop, or change any gout medication without consulting your doctor. If you develop a rash, blistering, fever, or any sign of a severe allergic reaction while taking allopurinol, stop the medication and seek immediate medical attention.